Organ-on-a-Chip Resources

Bridging the gap

Drug-induced liver injury (DILI) remains the most common cause for acute liver failure in the world and is a leading cause of compound attrition in drug discovery. Although sufficient at capturing most intrinsic events, current models used in drug discovery have limitations as they are not effective at predicting or understanding more complex DILI events in humans. Furthermore, for testing new human-specific modalities, cell lines/animal models are less suitable due to genetic or immunological response differences. Using the PhysioMimix® Organ-on-a-Chip (OOC) System, human and preclinical animal microphysiological system (MPS) models have been developed to bridge these gaps.

6 Challenges in ADME Drug Development

Explore the current challenges in profiling preclinical human ADME through key publications. Can advances in the human relevance of preclinical models improve estimations for safer and more efficient drug development?

Organ-on-a-Chip: Big Questions Surrounding Regulation and the Roadmap to Broad Adoption

To enhance and modernize the drug development process, many organizations are adopting Organ-on-a-chip (OOC) technologies into their workflows, from efficacy to safety assessment. With new developments in the technology and its applications evolve, questions and opportunities are arising, especially with regards to the regulatory landscape for NAMs , cost efficiency, and model confidence through standardization.

Liver-on-chip model and application in predictive genotoxicity and mutagenicity of drugs

Kopp et al., 2024. Current pre-clinical drug safety assessments lack a single, comprehensive test system for genotoxicity hazards identification. This study, aimed to develop an in vitro model to addresses this gap, looks at Organ-on-a-chip (OOC) technology as a solution. OOC present robust human metabolic activity and has the potential to assess all required endpoints for genotoxicity hazards identification, ultimately streamlining the process and eliminating the need for animal testing. This proof-of-concept experiment demonstrates the potential of PhysioMimix^® Liver-on-a-chip model as a promising tool for in vitro genotoxicity hazards identification, paving the way for a more streamlined and animal-free pre-clinical drug safety assessment process.

Defining validation criteria for a primary jejunum and primary hepatocyte dual-organ MPS

Improve in vitro to in vivo data translation for drug safety and efficacy with our fluidically-linked dual-organ MPS (microphysiological system); combining two well-characterized human Gut/Liver MPS – the RepliGut^® Jejunum and PhysioMimix® Liver MPS, in an interconnected model suitable for enhanced bioavailability profiling.

How in vitro human Gut/Liver models increase confidence in ADME estimations before human trials

This blog explores a world where novel multi-organ in vitro models, tiny replicas of the human intestine and liver, provide the key to unlocking a deeper understanding of how we Absorb, Distribute and Metabolize drugs.

Read more to discover why accurately estimating human ADME remains a challenge and a potential solution that enables greater confidence in lead candidates and a reduced risk of identifying poor oral bioavailability during first in human studies.

Organ-on-a-chip adoption: The roadmap to broader use

This blog explores challenges faced by the Pharmaceutical industry that pave the way for Organ-on-a-chip adoption and why it makes sense to start with toxicology workflows.

Developed the model, built the assay, now a focus on THROUGHPUT! The Liver-48, designed for industry adoption

The PhysioMimix® Liver-48 plate poster: CN Bio’s Multi-chip Liver-48 plate retains SBS-standard footprint, maintains Liver MPS functionality, and increasing throughput. By miniaturizing each chip, 48 tissues can be cultured per plate, 144 chips per PhysioMimix Single-organ HT System – more replicates and controls for fast, robust and cost-effective understanding of human drug safety earlier in the pipeline.

How Organ-on-a-Chip Addresses R&D Challenges

A blog that explores how organ-on-a-chip models are transforming liver disease research.

Developing a translational biomarker panel for use in pre-clinical advanced in vitro studies of Non-alcoholic steatohepatitis

Download the Application Note to discover a primary human Non-alcoholic steatohepatitis (NASH) microphysiological system (MPS) that more closely models the human liver and NASH disease.

Explore the model’s ability to recapitulate an advanced NASH phenotype (characterized by fibrosis), quantify the expression of biomarkers and assess the efficacy of four anti-NASH compounds that entered human clinical trials.

Understanding the mechanism of toxicity: OOC’s crucial role

It’s commonly acknowledged that the current drug discovery process is inefficient with large numbers of drugs failing in the clinic. Almost a third fail due to undetected toxicity issues. Countless more potential drugs fail due to misclassification by animal models.

Connecting the gut and liver

A human-relevant dual-organ microphysiological system connecting the gut and liver for preclinical profiling of oral bioavailability

Discover a new PhysioMimix® microphysiological system (MPS) that connects primary human RepliGut® and liver models to overcome the limitations of preclinical drug ADME profiling. Download the Application Note to explore the MPS’ evaluation of Temocapril and Midazolam, demonstrating its ability to provide more accurate predictions and change the risk calculus for safer and more efficient drug development.